Development and Optimization of Vaccines Based on Autologous Dendritic Cells (DC) is Activated by Cancer-Testis Antigens for the Treatment of Patients with Skin Melanoma

Nehaeva T. L., Baldueva I. A., Novik A. V., Danilova A. B., Vorobeychikov E. V., 
Vaal A. I., Pipia N. P.

N. N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation

Abstract.

This paper presents a detailed assessment of all stages of obtaining DC-vaccines and the expediency of their use for the treatment of patients with skin melanoma. There are showed statistical advantages of the selected approaches, causing controversy among different groups of researchers. As a result of this work it was reduced production cost of producingDC-vaccinesin5 times due to optimized use of growth factors GM-CSF and IL-4both imported and domestic production as well as adapted, optimized and implemented in clinical and laboratory practice for conducting specific immunological monitoring by means of the ELI Spot-analysis and cell ELISA. There are provided results of the clinical and immunological evaluation of the efficacy and safety of two types of therapeutic DC-vaccines(FDC-vaccine based on immature bone marrow DC swith photodynamic therapy and DCV-vaccine based on mature peripheral DCs) and adjuvant DCV in 42 patients with melanoma of the skin (218 cycles of vaccine). Use of standardized auto logo us DCs showed the safety and clinical efficacy in the two studied modes of therapy.

Keywords:

skin melanoma, immunotherapy, dendritic cells, DC-vaccine, optimization

REFERENCES
1. Baldueva I.A. Razrabotka, obosnovanie i ocenka sovremennoj bioterapii u bol'nyh s solidnymi opuholjami. Diss. PhD [Development, justification and assessment of the modern biotherapy at patients with solid tumors. Diss. PhD] St. Petersburg. 2008. 275 p.
2. Baryshnikov A.Ju., Nikitin K.D., Nikiforova A.N., Rubcova M.V. Comparative research of an adjuvanticity of antineoplastic vaccines on the basis of dendritic cages and in vitro dendrite. Allergologija i immunologija — Аллергология и иммунология. 2009. Vol. 10, No. 3. pp. 361–363.
3. Davydov M.I., Aksel' E.M. Statistics of malignant new growths in Russia and the CIS countries in 2007. Vestnik RONC im. N. N. Blohina RAMN — Journal of N. N. Blokhin Russian Cancer Research Center RAMS. 2009. Vol. 20. No. 3 (77), suppl. 1. pp. 153–156.
4. Demidov L.V., Harkevich G.Ju. Skin melanoma: stadirovaniye, diagnostics and treatment. Russkij medicinskij zhurnal — Russian medical magazine. 2003. No. 11 (11). pp. 658–665.
5. Kadagidze Z.G., Chertkova A.I., Slavina E.G. et al. Phenotype of immunocompetent cages and its value in the antineoplastic immune answer. Vestnik RAMN — Bulletin of the Russian Academy of Medical Science. 2011. No. 12. pp. 20—25.
6. Mihajlova I.N., Petenko N.N., Demidov L.V. Vaccinotherapy of a melanoma dendritic cages. Rossijskij bioterapevticheskij zhurnal — Russian biotherapeutic magazine. 2007. Vol. 6. No. 3. pp. 8–18.
7. Boyum A.A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity. Scand.J.Clin.Lab.Investig. 1968. Vol. 97. P. 51–76.
8. Castiello L., Sabatino M., Jin P. et al. Monocyte-derived DC maturation strategies and related pathways: a transcriptional view. Cancer Immunol.Immunother — 2011. — Vol. 60 (4). — P. 457—466.
9. Koido S., Homma S., Takahara A.et al. Immunologic monitoring of cellular responses by dendritic tumor cell fusion vaccines. J. Biomed Biotechnol. 2011. Vol. 77. pp. 1130–1141.
10. Korthals M., Safaian N., Kronenwett R. et al. Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J. Transl. Med. 2007. Vol. 25. pp. 5–46.
11. Mackiewicz J., Mackiewicz A. Design of clinical trials for therapeutic cancer vaccines development. Eur. J. Pharmacol. 2009. Vol. 625. pp. 84–93.
12. Morel P. A., Turner M. S.Designing the optimal vaccine: the importance of cytokines and dendritic cells. Open Vaccine J. 2010. Vol. 3. pp. 7–17.
13. Murphy J.F. Trends in cancer immunotherapy. Clin Med Insights Oncol. 2010. Vol. 14. pp. 67–80.
14. Ning J., Morgan D., Pamphilon D. A Rapid Culture Technique Produces Functional Dendritic-Like Cells from Human Acute Myeloid Leukemia Cell Lines. J. Biomed. Biotechnol. 2011. Vol. 2011 p. 9.
15. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest. 2003. Vol. 21 (6). pp. 873–886.
16. Oliver C., Jamur M.C.Immunocytochemical Methods and Protocols (Methods in Molecular Biology). Humana Press. Springer science Business Media, New York, London. 2010. 413 p.
17. O’Day S., Hodi F.S., McDermott D.F. et al. A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J ClinOncol. 2010. V. 28. I.18s. abstr 4.
18. Toh H.C., Wang W.W., Chia W.K. et al. Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients. Clin Cancer Res. 2009. Vol. 15 (24). pp. 7726–7736.
19. Tuyaerts S. Dendritic cell therapy for oncology roundtable conference. J. Immune Based Ther. andVacc. Vol. 9 (1). pp. 1476–1500.
20. Palucka K., Ueno H., Roberts L. et al. Dendritic cells: are they clinically relevant? Cancer J. 2010. Vol. 16 (4). pp. 318–324.

Authors
Nehaeva Tatyana L. 
petrovcenter.celltech@gmail.com,
Researcher of the Oncoimmunology Department
Baldueva Irina A. 
M. D., D. Sc (Medicine), Heado fthe Oncoimmunology Department
Novik Alexey V. 
PhD, Senior Researcher of the Oncoimmunology Department
Danilova Anna B. 
PhD, Senior Researcher of Department Oncoimmunology
Vorobeychikov Evgeniy V. 
PhD, Senior Researcher of the Oncoimmunology Department
Vaal Andrey I. 
PhD, Researcher of the Oncoimmunology Department
Pipia Nino P.
graduate student of the Oncoimmunology Department
N. N. Petrov Research Institute of Oncology
197758, St.- Petersburg, Russian Federation, 68 Leningradskaya str., Pesochny